Kolexia
Cussac Vincent Biologie médicale
Cussac Vincent
Biologie médicale
Centre Hospitalier du Mans
Le Mans, France
86 Activités
1.3 K Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Hémophilie A Maladies de von Willebrand Hémorragie Hémophilie B Insuffisance pancréatique exocrine Hépatite Hémarthrose Syndrome des plaquettes grises Macroglobulinémie de Waldenström

Collaborateurs

Voir plus
Pan-Petesch Brigitte
Pan-Petesch Brigitte
Hôpital Morvan, Brest, France
Rose Johann
Rose Johann
Centre Hospitalier du Mans, Le Mans, France
Trossaert Marc
Trossaert Marc
Hôpital Hôtel-Dieu Nantes, Nantes, France
Guillet Benoit
Guillet Benoit
Hôpital Pontchaillou, Rennes, France

Industries

Voir plus
Schlesinger Group France
11 collaboration(s)
Dernière en 2023
A+A
10 collaboration(s)
Dernière en 2023
Octapharma
7 collaboration(s)
Dernière en 2022
Takeda Pharmaceutical
5 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
Key Drivers of Coagulation Factor Use in Von Willebrand Disease During Hospitalization: An Overview of the French BERHLINGO Cohort.
Clinical drug investigation   30 novembre 2023
Efficacy and safety of turoctocog alfa in patients with hemophilia A requiring surgical procedures: A multicentre retrospective study.
Transfusion   18 octobre 2023
SENIORHEMO: Objective and Perceived Health Status of Elderly People With Moderate or Severe Haemophilia in France: an Ancillary Study of the FranceCoag Registry
Essai Clinique (Assistance publique - Hôpitaux de Marseille)   07 juin 2023
PO080 FRENCH REAL-WORD DATA ON RIX-FP PROPHYLAXIS USE IN PATIENTS WITH HAEMOPHILIA B
16th Annual Congress of European Association for Haemophilia and Allied Disorders 2023, 7–10 February 2023, Manchester   05 février 2023
rFVIII-Fc in severe haemophilia A: The incentive switch in case of high risk of joint bleedings.
European journal of clinical investigation   27 juin 2022
Real-world Use of FVIII in People with Severe Hemophilia A without Inhibitor on Prophylaxis, Comparing Switched to rFVIII-Fc versus Non-switched Patients: A Multicentre, Retrospective, Non Interventional, before-after Study with the French Nationwide Claims Database (MOTHIF-II)
Special Issue: Abstracts of the ISTH 2021 Virtual Congress of the International Society of Thrombosis and Haemostasis, July 17–21, 2021   07 octobre 2021
Real-world Annual Bleeding Rate in People with Severe Hemophilia A without Inhibitor on Prophylaxis, Comparing Switched to rFVIII-Fc versus Non-switched Patients: A Multicentre, Retrospective, Non interventional, before-after Study with the French BERHLINGO Database (MOTHIF-II)
Special Issue: Abstracts of the ISTH 2021 Virtual Congress of the International Society of Thrombosis and Haemostasis, July 17–21, 2021   07 octobre 2021
Genomic analysis of primary and secondary myelofibrosis redefines the prognostic impact of ASXL1 mutations: a FIM study.
Blood advances   31 mai 2021
Efficacy and safety of a recombinant Von Willebrand Factor treatment in patients with inherited Von Willebrand Disease requiring surgical procedures.
Haemophilia : the official journal of the World Federation of Hemophilia   06 février 2021
ABS219 | EFFICACY AND SAFETY OF A RECOMBINANT VON WILLEBRAND FACTOR TREATMENT IN PATIENTS WITH INHERITED VON WILLEBRAND DISEASE REQUIRING SURGICAL PROCEDURES: A FRENCH MULTICENTRE RETROSPECTIVE STUDY
Virtual Congress of the European Association for Haemophilia and Allied Disorders 2021 3‐5 February 2021   02 février 2021